Navigation Links
Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
Date:3/11/2009

current liabilities 4,877 3,682 Long-term liabilities: Convertible debt 553 2,764 Debt discount (66) (651) Net long-term convertible debt 487 2,113 Asset retirement obligation 2,217 2,217 Total liabilities 7,581 8,012 Stockholders' equity (deficit): Common stock; $.01 par value; authorized shares 500,000,000; issued and outstanding shares, 122,494,010 in 2008 and 121,904,312 in 2007 1,225 1,219 Additional paid-in capital 342,378 341,270 Accumulated deficit (346,426) (330,759) Accumulated other comprehensive loss: Unrealized loss on investment - (242) Net stockholders' equity (deficit) (2,823) 11,488 Total liabilities and stockholders' equity (deficit) $4,758 $19,500

                              INSMED INCORPORATED
                   Consolidated Statements of Operations
              (in thousands, except per share data - unaudited)

                               Three Months Ended         Twelve Months Ended
                                   December 31,               December 31,
                               2008          2007         2008          2007

    Sales, net                   $-            $-           $-          $423
    Royalties                    61            41          144           121
    License income                -            62            -         1,607
    Grant revenue                 -             -        1,044             -
    Other expanded access
     Program income, net      2,878         2,032       10,511         5,430
      Total revenues  
'/>"/>
SOURCE Insmed Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
3. Insmed to Appeal Delisting Notification From Nasdaq
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
6. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
7. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
8. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
11. Insmed to Present at CBI Follow-On Biologics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Gene synthesis and bioengineering company ... into a technology access and services agreement with ... proprietary protein engineering technology, known as “ProteinGPS®” to ... extremely excited that the global leader ADM has ... bioengineering technology has now been validated through many ...
(Date:12/17/2014)... 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a primary commercial focus on China ... a Type C meeting with the U.S. Food and ... held in February 2015.  During this meeting the Company ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  BrainStorm ... leading developer of adult stem cell technologies for neurodegenerative ... Ltd. was awarded a grant of approximately $1.1 million ... Chief Scientist (OCS).  This is the eighth year that ... the Office of the Chief Scientist, which is part ...
(Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma A/S, ... technology to address significant unmet medical needs, today ... Phase 2 pediatric study to evaluate once-weekly TransCon ... or GHD.  This interim analysis consists of 25 ... enrollment in the study, completing all six months ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
... Corp ., a non-profit development company that helps small businesses, ... technology businesses. , ,MDC said it has closed on loans ... off of Lucigen Corp. , and to BioSystem ... Contest. , ,C5-6 Technologies, which will develop enzymes used to ...
... series of articles on developing start-up companies in the technology or ... entity. , , Madison, Wis. - Now ... to the type of entity to use, you should have concerned ... people think of first. Income taxes depend upon the type of ...
... - Jim Rice, who has served as president and CEO ... the past year, will leave ITAWi after an agreed-upon transition ... organization announced. , ,ITAWi's Board of Director has begun ... will assume Rice's duties until a replacement is found. Rice ...
Cached Biology Technology:Early Stage: Step 6 - Taxes, taxes, taxes! 2Early Stage: Step 6 - Taxes, taxes, taxes! 3Early Stage: Step 6 - Taxes, taxes, taxes! 4Rice to leave Wisconsin technology association 2
(Date:12/10/2014)... 2014     ...   Jifflenow, a leading ... for business-to-business (B2B) events, today announced a partnership ... near-field communication (NFC), Bluetooth low energy (BLE), and ... , Jifflenow will integrate its meeting ...
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
(Date:12/3/2014)...   Marvin Test Solutions , a trusted ... military, aerospace, and manufacturing organizations, today announced the ... TS-900 PXI semiconductor test platform . The TS-960 ... to customers at a fraction of the footprint ... "Our semiconductor customers asked for ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... Virology of the GSF National Research Center for ... Research Centres) the group is continuing to search for ... of a prion infection. In collaboration with colleagues from ... Heidelberg, the group used micro-array technologies micro-arrays ...
... plant cell biologist at UC Riverside has received a ... investigate how plant stem-cells maintain their identity and how ... According to G. Venugopala Reddy, the principal investigator of ... on plants, has potential to lead to better insights ...
... infant formula-- may reduce a babys susceptibility to rotavirus ... a University of Illinois study published in Septembers Journal ... diarrhea in infants, affecting virtually all children before age ... dehydration, doctors visits, and parents missing work to care ...
Cached Biology News:Prions and retroviruses -- an unholy alliance? 2UCR plant cell biologist to study how plant stem cells maintain and change their identity 2Soy isoflavone may inhibit common gastrointestinal illness in infants 2
...
Human Regulatory T cell Staining Kit #2 (w/ APC Foxp3 PCH101, FITC CD4, PE CD25)...
Goat anti-VAV2 Class: Antibody Product Group: Miscellaneous Antibody...
Rabbit polyclonal to M13 Bacteriophage Coat Proteins ( Abpromise for all tested applications)....
Biology Products: